TY - JOUR
T1 - Non-AIDS-defining malignancies among HIV-infected patients in the highly active antiretroviral therapy era
AU - Bedimo, Roger
N1 - Funding Information:
Dr. Bedimo has received research grants from Abbott Laboratories, Bristol-Myers Squibb, and Merck; received continuing medical eduction lecture support from Abbott Laboratories, Bristol-Myers Squibb, GlaxoSmithKline, Merck, and Tibotec; received speaker fees from Merck; and served on the advisory board for Merck.
PY - 2008/8
Y1 - 2008/8
N2 - In the highly active antiretroviral therapy (HAART) era, the incidence of AIDS-defining malignancies (ADMs) has declined significantly. On the other hand, the incidence of other malignancies not known to be associated with immunosuppression (non-ADMs) has not changed and remains significantly higher than in the general population. Some recent controlled studies even suggest that the incidence of selected non-ADMs has increased in the HAART era. These trends warrant a high index of suspicion for malignancies among HIV care providers and a renewed focus on understanding the mechanisms underlying the increased rates. Potential explanations for the higher non-ADM rates include longer survival of patients with HIV on HAART, with only partial immune recovery achieved in most patients; high incidence of human papillomavirus, Epstein-Barr virus, and hepatitis C virus coinfection in patients with HIV infection; and potential oncogenicity of long-term HIV infection or of long-term HAART.
AB - In the highly active antiretroviral therapy (HAART) era, the incidence of AIDS-defining malignancies (ADMs) has declined significantly. On the other hand, the incidence of other malignancies not known to be associated with immunosuppression (non-ADMs) has not changed and remains significantly higher than in the general population. Some recent controlled studies even suggest that the incidence of selected non-ADMs has increased in the HAART era. These trends warrant a high index of suspicion for malignancies among HIV care providers and a renewed focus on understanding the mechanisms underlying the increased rates. Potential explanations for the higher non-ADM rates include longer survival of patients with HIV on HAART, with only partial immune recovery achieved in most patients; high incidence of human papillomavirus, Epstein-Barr virus, and hepatitis C virus coinfection in patients with HIV infection; and potential oncogenicity of long-term HIV infection or of long-term HAART.
UR - http://www.scopus.com/inward/record.url?scp=48949104405&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=48949104405&partnerID=8YFLogxK
U2 - 10.1007/s11904-008-0022-4
DO - 10.1007/s11904-008-0022-4
M3 - Article
C2 - 18627663
AN - SCOPUS:48949104405
SN - 1548-3568
VL - 5
SP - 140
EP - 149
JO - Current HIV/AIDS Reports
JF - Current HIV/AIDS Reports
IS - 3
ER -